Aman's Global Market Intelligence

1 · Executive dashboard

CPI gate at 14:30 Italy

Regime call: neutral with a risk-off skew. U.S. stocks fell for a second day and mega-cap tech weakened, while oil extended to a sixth daily gain and geopolitical shipping risk intensified. The offset is healthy S&P breadth, stronger small caps, a 4% Kospi surge and slightly positive U.S. futures. Inference: this is selective de-risking rather than liquidation, but the simultaneous oil/rates/CPI setup makes pre-data risk unattractive.

S&P 5007,728.20−0.32% Tue

Nasdaq Composite26,445.45−0.60%

Dow Jones53,791.85−0.34%

Russell 20003,027.12+0.32%

VIX15.28−1.16%

U.S. 2Y4.217%Tue close, CNN

U.S. 10Y4.692%Tue close, CNN

Dollar index99.88+0.07% live

WTI$83.71+0.61% live

Spot gold$4,400.44+0.77% live

Market	Latest / move	Session represented	Read-through
S&P 500 e-mini	7,757.3 · +0.13%	Reuters Asian/early-Europe snapshot	Small positive indication, not conviction before CPI
Nikkei 225	about +0.8%	Live after reopening from holiday	Yen weakness supportive; intervention risk remains
Hang Seng	25,349 · −1.18%	Latest live level independently shown by WSJ	China/HK lagged regional tech strength
Shanghai Composite	3,943 · +0.24%	Latest live level independently shown by WSJ	Modest gain
Kospi	about +4.0%	Live; Reuters	Tech-led regional outperformance
ASX 200	9,202 · −0.53%	Latest live level; WSJ	Commodity/rates sensitivity
Euro STOXX 50 / DAX futures	flat / −0.04%	European pre-open	No directional edge
FTSE futures	−0.19%	European pre-open	Oil benefit offset by broader caution

1 · CPI is the immediate gate

Confirmed: BLS releases July CPI at 08:30 ET / 14:30 Italy. Reuters consensus is +0.1% m/m and 3.4% y/y versus June's −0.4% and 3.5%. Inference: a hot print is especially problematic while oil is rising; a soft print could relieve yields but will not remove energy risk.

2 · Hormuz/Red Sea risk rose

Reuters reported separate U.S. and Houthi attacks on shipping; four crew members were killed, and tracked Hormuz traffic fell to a one-week low. Brent reached $89.46 and was poised for a sixth gain. This is a confirmed supply-risk channel, not a forecast of disruption.

3 · AI results split demand from finance

SMCI showed powerful revenue/margin acceleration, while CoreWeave doubled revenue and backlog reached $104B. Yet CoreWeave's $640M quarterly net interest expense and $35–39B FY capex guide sharpen the question: who earns durable free cash flow from AI buildout?

2 · Market-moving analysis

Confirmed facts versus inference

Macro, central banks & liquidity

The Fed held its target range at 3.50–3.75% on July 29, with three dissents favoring a 25 bp hike. Official Aug. 10 Treasury closes were 4.25% (2Y) and 4.72% (10Y); CNN's later Aug. 11 market snapshot showed 4.217% and 4.692%.
Reuters said money markets assigned roughly even odds to a September hike. Boston Fed President Susan Collins was reported open to a hike if inflation stays high. Market pricing is volatile and not a probability guarantee.
July payrolls fell 23,000 while unemployment was 4.1%, leaving a difficult inflation/growth mix. Today's CPI does not include the newest oil jump.
Japanese 5Y and 2Y yields reached 2.12% and 1.645%, respectively, as markets priced earlier BOJ tightening. The yen weakened to about 159.38/$ after coordinated intervention last week.
Next: July PPI Thursday and retail sales/Michigan sentiment Friday. The inflation narrative therefore remains a multi-day process, not a single print.

Geopolitics, rotation & market structure

Tuesday's S&P and Nasdaq fell, but S&P advancers beat decliners 1.2-to-1 and Russell rose 0.32%. Energy gained 1.1%, evidencing rotation rather than indiscriminate selling.
Alphabet fell 3.8% and Amazon 2.1%; NVIDIA finished nearly flat. Financial alternatives rallied after joining reported AI compute-financing platforms.
U.S. exchange volume was 15B shares versus a 20-day 17.6B average. Unusual moves should therefore be treated cautiously: the session was relatively light.
North Korea launched a ballistic missile; Taiwan objected to planned China–Indonesia naval drills east of the island. These add tail risk but no direct earnings impact is assumed.
Inference: energy, defense and select financials have the near-term relative-strength advantage, while long-duration themes need lower yields or strong cash-flow evidence.

AI earnings: what was actually verified

SMCI: Q4 sales $11.12B (+93% y/y), gross margin 17.5%, net income $1.18B and operating cash flow $747M. FY27 sales guide is $65–72B; Q1 guide $14.5–15.5B.
SMCI counterweight: FY26 operating cash flow was negative $6.81B as inventory grew by $8.88B and receivables by $3.92B. Cash $7.5B versus bank debt/convertibles $8.7B; figures are preliminary, and an independent export-control transaction review continues.
CoreWeave: Q2 revenue $2.575B (+112%), adjusted EBITDA $1.51B, but GAAP net loss $626M and net interest expense $640M. Backlog was ~$104B plus >$25B net new early-Q3 commitments.
CoreWeave outlook: Q3 revenue $3.45–3.60B, interest $860–940M and capex $11.5–13.5B; FY revenue $12.4–13.2B and capex $35–39B. Strong demand is confirmed; shareholder economics remain financing-sensitive.

Company / regulatory checks

NVIDIA's $217.50 close was essentially flat despite the reported >$500B third-party infrastructure financing initiative. No same-cutoff primary NVIDIA release was found; the claim remains attributed to Reuters.
Novo announced an AWS AI drug-discovery partnership Aug. 10 after raising its FY outlook Aug. 4. This is strategic but not a peptide clinical readout.
No new, directly verified focused peptide-drug FDA decision or pivotal data release was found before cutoff. Exact binary dates require issuer/FDA confirmation; none is invented here.
Quantum pure plays rose modestly Tuesday (IONQ +2.14%, RGTI +2.49%, QBTS +0.20%) according to Nasdaq closes, without a verified new same-day fundamental catalyst in this research set.

3 · Theme dashboards

AI / data centers Demand strong, funding costly

Leaders: SMCI margin recovery and guide; CoreWeave backlog/active power; Jabil +5.94% after a verified UBS upgrade.
Laggards: Alphabet −3.84%, Amazon −2.09%; the Nasdaq fell 0.60%.
Stack read-through: server, networking, liquid cooling, power and financing demand is real. CRWV's interest/capex profile and SMCI's working-capital absorption show that revenue growth alone is insufficient.
Next: Cisco after today's close, Applied Materials Thursday, NVIDIA Aug. 26.
Risks: leverage, utilization, customer concentration, export controls, power delivery, working capital, dilution and valuation.

Quantum computing Venture-like public equities

Tuesday closes: IONQ $43.44 (+2.14%), RGTI $18.09 (+2.49%), QBTS $20.23 (+0.20%). These moves do not establish trend confirmation.
Prior verified fundamentals remain mixed: revenue growth and liquidity coexist with heavy losses, tiny revenue bases versus valuation, and long technical roadmaps.
Leader by evidence quality: diversified enablers such as MSFT/NVDA/IBM remain preferable for core capital; pure plays belong only in explicitly speculative sleeves.
Risk: contract lumpiness, roadmap slips, acquisitions, warrants/dilution and squeeze. No borrow availability or cost is asserted.

Peptide / metabolic biotech Commercial strength, event risk

Tuesday focused closes: LLY $1,215.02 (−1.37%), NVO ADR $47.17 (−1.17%), VKTX $33.80 (−1.86%). The whole group retraced.
LLY's prior verified Q2 evidence remains strongest: revenue $23.0B (+48%), Mounjaro +91%, Zepbound +46% and FY revenue guide $85–87B.
Novo's raised outlook and AWS discovery partnership improve strategic visibility, but competitive efficacy, pricing and access remain central.
For development-stage names, require phase/endpoints, statistical and safety detail, cash runway and regulatory path before acting. No fresh pivotal peptide dataset was verified today.

4 · Ranked ideas

Conditional paper-tracking; scores are not probabilities

#1 SMCI · Super Micro Computer Bullish only on confirmation

Nasdaq · high-risk AI systems / cooling · preliminary financials, governance, working-capital and export-control risk

Day trade: post-CPI only1–4 weeks: applicable with price confirmation3–12+ months: watch, not core yet

Uncertain direction / thesis: upside is possible if the market rewards Q4 margin and FY27 growth, but weak cash conversion and review risk can overwhelm the headline beat.

Catalyst / evidence: Q4 sales $11.12B, gross margin 17.5%, non-GAAP EPS $1.70; FY27 sales guide $65–72B and >$60B orders/backlog.

Counterargument: FY26 operating cash burn $6.81B, inventory +$8.88B, $8.7B debt/convertibles, preliminary numbers and board review.

Entry / confirmation: only after CPI and a sustained reclaim of $32 with strong volume; prefer a successful retest rather than opening-gap chase.

Invalidation / downside: close below $30.90/$30.50 area, margin-guide reversal, order cancellations, adverse review result or worsening operating cash flow.

Key risks: customer concentration, working capital, dilution, export controls, tariffs, component mix and extreme earnings volatility.

Confidence

Risk

Opportunity

#2 LLY · Eli Lilly Conditional accumulation

NYSE · mega-cap profitable peptide/metabolic leader · premium valuation, pricing/access and pipeline risk

Day trade: no pre-CPI entry1–4 weeks: applicable above support3–12+ months: applicable

Uncertain direction / thesis: commercial execution and guidance support relative leadership, but Tuesday's reversal shows that premium valuation needs continued estimate support.

Evidence / catalyst: Q2 revenue +48%; Mounjaro +91%, Zepbound +46%; raised $85–87B FY revenue guide. Pipeline and manufacturing execution remain ongoing catalysts.

Counterargument: realized price pressure, payer policy, competition and clinical/regulatory outcomes can compress the multiple.

Entry / confirmation: hold/reclaim $1,220 after CPI or a controlled support test near $1,200; avoid a gap chase.

Invalidation / downside: close below $1,184, estimate cuts, access deterioration, safety signal or manufacturing shortfall.

Key risks: reimbursement, Novo/emerging competitors, concentration, safety, supply and valuation.

Confidence

Risk

Opportunity

#3 CRWV · CoreWeave Avoid chasing · not a short

Nasdaq · high-risk AI cloud · leverage, capex, concentration and squeeze risk

Day trade: avoid post-result volatility1–4 weeks: wait for cash-flow proof3–12+ months: financing watch

Uncertain direction / thesis: demand may lift the stock, but $626M quarterly net loss, $640M net interest and a $35–39B FY capex guide make equity economics unusually sensitive to capital markets.

Evidence / catalyst: revenue +112% to $2.575B, backlog ~$104B plus >$25B early-Q3 commitments; Q3 revenue guide $3.45–3.60B.

Counterargument: 59% adjusted EBITDA margin, rapidly rising active/contracted power and customer demand could create major operating leverage.

Confirmation: funded capex, lower interest burden, positive adjusted operating trajectory and credible free-cash conversion; price must hold above the post-result range.

Invalidation / downside: avoid view weakens on durable free cash flow; long thesis fails on financing stress, backlog slippage or loss of key customers.

Key risks: debt/refinancing, dilution, concentration, GPU supply, power execution, utilization and squeeze. No borrow claim.

Confidence

Risk

Opportunity

#4 RGTI / IONQ / QBTS basket Avoid chasing · not a short

Nasdaq/NYSE · speculative quantum pure plays · small/mid-cap, dilution and squeeze risk

Day trade: unsuitable for most1–4 weeks: no clean evidence edge3–12+ months: milestone-only watch

Uncertain direction / thesis: Tuesday bounces may continue, but price action lacked a new verified fundamental catalyst and commercialization remains early.

Evidence / counter: technical progress, government interest and liquidity are positives; revenue bases, losses, roadmap duration and valuations are negatives.

Confirmation: recurring funded commercial wins, improving gross economics and verified roadmap milestones—not social-media enthusiasm.

Invalidation / downside: avoid stance changes with material recurring revenue and operating leverage; downside can be severe on delays or financing.

Key risks: contract timing, technical failure, dilution/warrants, M&A integration, volatility and squeezes.

Risk class: venture-like public equities; position sizing, if any, should assume possible 30–50% drawdowns.

Confidence

Risk

Opportunity

Watchlist · five maximum

NVDA Watch

Nasdaq · mega-cap · C/R/O 78/67/68. Day/swing only after CPI; long-term applicable. Near-flat Tuesday despite financing news is neutral. Confirm above recent $224 area with breadth; invalidate below the $216–217 zone. Aug. 26 earnings are key. Risks: valuation, export controls, customer concentration, capex and power.

MSFT Diversified AI/quantum

Nasdaq · mega-cap · C/R/O 77/55/66. Swing/investment applicable after rates stabilize. Tuesday −0.44%. Cloud cash flow offers lower binary exposure than pure plays. Confirm relative strength with 10Y below 4.65%; invalidate on cloud/AI monetization slowdown. Risks: capex, regulation and valuation.

CSCO Tonight's networking read

Nasdaq · large-cap · C/R/O 70/58/62. No pre-earnings position. Watch AI networking orders, backlog conversion, enterprise demand, margins and guide after close. Invalidation is weak orders or margin compression. Earnings gaps and macro sensitivity apply.

NVO Peptide challenger

NYSE ADR · large-cap · C/R/O 71/70/62. Swing/investment watch, not a day-trade priority. Raised outlook and AWS partnership are positives; Tuesday −1.17%. Require stabilization above $47 and estimate support. Risks: competition, trial outcomes, access/pricing and currency.

JBL AI manufacturing strength

NYSE · large-cap supplier · C/R/O 62/68/57. Day/swing only on non-chasing setup. Tuesday +5.94% after a verified UBS upgrade. Wait for pullback/hold rather than follow the gap. Invalidate on full reversal. Risks: analyst-driven move, customer concentration, cyclicality and margins.

5 · Changes versus Aug. 11

Regime: remains neutral/event-risk elevated, but the skew worsens to risk-off because oil extended higher, shipping fatalities were reported and mega-cap tech weakened for a second day.
LLY paper call: Tuesday fell 1.37% to $1,215.02, losing the prior preferred $1,220 hold but remaining above $1,184 invalidation. It moves from clear #1 to conditional #2; no success is claimed.
SMCI: upgraded from binary watch to conditional bullish #1 after verified Q4 margin, earnings and FY27 guidance. Confidence is capped by preliminary reporting, −$6.81B FY operating cash flow and the export-control review.
CRWV: moved from binary watch to avoid-chasing. Revenue/backlog were strong, but interest expense and capex guidance materially worsened the equity-risk assessment.
Quantum avoid calls: Tuesday rebounds of 0.2–2.5% worked against the one-day avoid stance. The thesis is not invalidated because it was explicitly “avoid chasing,” not a short or forecast of immediate declines.
NVDA: remains watch; Tuesday's $217.50 close did not reclaim the prior $224 confirmation and stayed just above the $216–217 downside zone.

6 · Important 7–30 day catalysts

Times ET unless stated; verify close to event

Aug. 12 · 08:30 — U.S. July CPI + real earnings

BLS-confirmed. Central cross-asset gate; Reuters consensus headline +0.1% m/m, 3.4% y/y.

Aug. 12 · after close — Cisco FY26 results

AI networking orders, enterprise demand, margins and outlook.

Aug. 13 · 08:30 — July PPI and weekly claims

Inflation pipeline and labor confirmation.

Aug. 13 · after close — Applied Materials results

Foundry/logic, memory, advanced packaging, China/export and capex commentary.

Aug. 14 — Retail sales and Michigan sentiment

Consumer resilience and inflation expectations amid higher oil.

Aug. 18 — Import/export prices

BLS-confirmed; trade-price inflation channel.

Aug. 19 · 14:00 — FOMC minutes

Detail behind three July dissents favoring a hike.

Aug. 26 — NVIDIA results

Rubin/Blackwell demand, networking, supply, China/export exposure, gross margin and customer funding.

Aug. 17–Sep. 11 — Peptide/biotech verification window

Monitor issuer IR, FDA/EMA and ClinicalTrials.gov for focused trial/regulatory updates. No exact unverified PDUFA is asserted.

7 · Bottom line by horizon

Current session / day trade

No compelling pre-CPI trade. After the release, SMCI has the strongest fresh catalyst only if it holds/reclaims $32 with volume and yields do not spike. Otherwise stay flat; do not chase CRWV or quantum gaps.

1–4 week swing

LLY and SMCI, conditional. LLY needs $1,220 recovery or support near $1,200; SMCI needs post-result price confirmation plus cash-flow skepticism priced in. NVDA remains a watch above $224.

3–12+ month investment

Prefer cash-generative leaders. LLY for peptide leadership and MSFT/NVDA for diversified AI exposure. Treat SMCI as high-risk until working capital normalizes; avoid making CoreWeave or quantum pure plays core holdings without free-cash/recurring-revenue proof.

Biggest risk: hot CPI plus continued shipping disruption drives oil and yields higher together. Upgrade to risk-on: benign CPI, 10Y below 4.65%, WTI back below $80 and positive breadth. Downgrade to risk-off: WTI above $85, 10Y above 4.80%, S&P breaks below Tuesday's range broadly, or AI guidance/cash conversion deteriorates. These are analytical invalidation markers, not predictions.

Sources & data quality

Data-quality panel

U.S. cash indices, VIX, Russell, rates and commodities were cross-checked across Reuters, CNN, CNBC/Yahoo and Nasdaq. Major index closes agree. Reuters provided the latest 06:34 UTC global-market snapshot.
Asian moves are near-cutoff live figures, not final for every venue. Reuters supplied regional direction; WSJ levels independently cross-checked Nikkei/Hang Seng/Shanghai/Kospi/ASX. European values are futures/pre-open, not cash closes.
Nasdaq's API directly returned Aug. 11 closes for focused U.S. equities and ETFs. Yahoo's chart API failed with HTTP 429; Nasdaq, Reuters, CNN and CNBC were used instead. Stooq CSV attempts returned HTTP 404 because the requested endpoint/path was unavailable. FRED API returned HTTP 400 without a key; official Fed H.15 succeeded.
CoreWeave and Super Micro figures are from primary IR releases/presentations. SMCI labels its data preliminary/unaudited; this limitation is material. CoreWeave guidance comes from its official outlook deck.
NVIDIA's reported >$500B financing initiative is Reuters-sourced. The attempted NVIDIA IR press-release URL returned a page-not-found, so the report does not upgrade that claim to a primary-source fact.
Peptide checks included Novo, Lilly and Viking IR/news paths plus current industry reporting. Lilly and Viking attempted URLs returned not-found pages; Novo's official newsroom succeeded. No focused same-cutoff FDA/clinical decision is claimed.
Technical levels are conditional reference zones from recent closes/ranges, not guarantees. Confidence is evidence quality; Risk rises with risk; Opportunity is conditional attractiveness—not probability of profit.